As per the American Cancer Society, in the year 2016, nearly 1,685,210 new cancer cases were registered in the U.S. In addition, the haemostatic factor plays an important role in tumour progression and haemostatic components and cancer biology are interconnected in various ways. An imbalance of the haemostatic system in cancer patients raises their chances of developing thrombosis, haemorrhage or both. Research has indicated that malignancy affects the haemostatic system and vice versa. An increasing prevalence of cardiovascular diseases is expected to boost the global market for coagulation analysers during the forecast period. In light of this, coagulation tests such as PT/INR are commonly used blood tests to identify the risk of cardiovascular diseases. As per the data provided by WHO, 17.5 million people across the world die from cardiovascular diseases every year, which accounts for 31 percent of all the deaths globally. Growing Prevalence of Cardiovascular Diseases and an Increase in the Number of Cancer Patients Fuelling Revenue Growth of the Coagulation Analysers MarketĬardiovascular diseases are one of the leading causes of deaths in the world and are considered as a global disease burden. The estimates point to a revenue growth from US$ 756 Mn in the year 2017 to US$ 1,514 Mn by 2027 end, resulting in a CAGR of 7.2% during the period of assessment. The report presents the value forecast of the global coagulation analysers market and provides useful insights into the factors driving market growth as well as the factors restricting market growth. The Coagulation Analyzers Market is projected to reach a value of US$ 1,514 Mn at the end of the year 2027, exhibiting a CAGR of 7.2%- Report by Future Market InsightsĪ new report published by Future Market Insights titled ‘ Coagulation Analysers Market : Global Industry Analysis and Opportunity Assessment’ studies the performance of the global coagulation analysers market over a 10-year assessment period from 2017 to 2027.
0 kommentar(er)
